Purpose of Review <p>Ulcerative colitis (UC) is a recurrent, chronic inflammatory bowel illness that has grown more common worldwide and has substantial adverse impacts on both health and the economy. Despite advances in understanding its multifactorial pathogenesis encompassing genetic, environmental, microbial, and immunological factors current therapies remain limited by adverse effects, costs, and fragmentary efficacy. This review seeks to provide a comprehensive synthesis of recent developments in UC pathogenesis, epidemiology, and treatment, with a particular focus on the pharmacological potential of flavonoids, notably luteolin (LUT), as novel adjuncts or alternatives to conventional therapies.</p> Recent Findings <p>Recent research has shown that UC has grown more prevalent globally, with sharp rises in Asian populations. The involvement of gut microbiota imbalance, poor epithelial barrier function, and mucosal immune dysregulation is highlighted by developments in our understanding of UC pathogenesis. Preclinical models have shown that flavonoids, and LUT in particular, have strong anti-inflammatory, antioxidant, and immunomodulatory properties. These include immune response control, cytokine production regulation, and inhibition of the Nuclear factor (NF)-κB and Mitogen-Activated Protein Kinase&#xa0;(MAPK) pathways. The extraction, purity, and bioavailability of LUT have all been enhanced by technological developments. Emerging human ex vivo studies and pharmacokinetic investigations have revealed that LUT circulates primarily in metabolized forms like monoglucuronides, but it can also be locally reactivated at inflammatory sites, demonstrating biological activity, even though the majority of findings are derived from preclinical models. LUT demonstrated its translational potential in inflammatory circumstances by inhibiting Tumor Necrosis Factor (TNF)-α-induced ICAM-1 expression in human endothelial cells.</p> Summary <p>The clinical state of UC is challenging due to its complicated aetiology and the limits of existing treatments. Although there is a multitude of preclinical research demonstrating the therapeutic potential of flavonoids such as LUT in regulating important inflammatory and immunological processes in UCs, there is lack of human clinical evidence to support these benefits. The entire therapeutic potential of LUT must be reached in order to enhance outcomes for UC patients, and this translational gap must be closed by well planned clinical studies.</p>